Skip to main content
  • Home
  •  A Race Against Time: Accelerating the Adoption of GDMT in Heart Failure

A Race Against Time: Accelerating the Adoption of GDMT in Heart Failure

  • Heart Failure

Available Credit:

  • Not accredited

Course Published On:

Course Expiry Date:

A Race against Time: Accelerating the Adoption of GDMT in Heart Failure
No ratings


This symposium emphasises the critical role of accurate and rapid diagnosis in enabling physicians to quickly start guideline-directed medical therapy. Prof Antoni Bayes-Genis (University Hospital Germans Trias i Pujol, Barcelona, ES), Dr Lisa Anderson (St George's Hospital, London, UK) and Dr Stephen Greene (Duke University School of Medicine, Durham, US) discuss and reflect on current guidelines and emerging algorithms, offering insights into the challenges surrounding delays and adoption rates in both community and hospital settings and their profound impact on patient care.

Presented, and recorded, at HFA 2024 in Lisbon, PT

Support Statement

This Satellite Symposium was supported by an unrestricted educational grant from AstraZeneca who had no involvement in the content.

Target Audience

  • Cardiologists
  • Heart Failure Specialists

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Recall guideline recommendations for the use of NT-proBNP in heart failure
  • Describe current practices in heart failure diagnosis and the impact on treatment outcomes
  • Develop an optimised approach to the timely diagnosis and management of heart failure
Register now Log in





1 Welcome and Introduction 4m 44s Lisa Anderson
2 Implementing GDMT: What Should We Be Doing? 15m 59s Antoni Bayés-Genís
3 Implementing GDMT: What Is Really Happening? 17m 13s Lisa Anderson
4 The Implication of Delayed Diagnosis and Sub-Optimal GDMT 14m 13s Stephen J Greene
5 Panel Discussion & Audience Q&A - Accelerating the Adoption Of GDMT 2m 32s Antoni Bayés-Genís
6 Key Take-Home Messages and Close 43s Antoni Bayés-Genís

Welcome and Introduction

Duration: 4m 44s

Speakers: Lisa Anderson


Implementing GDMT: What Should We Be Doing?

Duration: 15m 59s

Speakers: Antoni Bayés-Genís


Implementing GDMT: What Is Really Happening?

Duration: 17m 13s

Speakers: Lisa Anderson


The Implication of Delayed Diagnosis and Sub-Optimal GDMT

Duration: 14m 13s

Speakers: Stephen J Greene


Panel Discussion & Audience Q&A - Accelerating the Adoption Of GDMT

Duration: 2m 32s

Speakers: Antoni Bayés-Genís


Key Take-Home Messages and Close

Duration: 43s

Speakers: Antoni Bayés-Genís


Antoni Bayés-Genís

Antoni Bayés-Genís

Hospital Germans Trias i Pujol, Barcelona, ES

Antoni Bayés-Genís is Head of the Heart Institute at the University Hospital Germans Trias i Pujol in Barcelona, and Professor of Cardiology at the Universitat Autònoma de Barcelona in Barcelona, Spain.

View full profile


Lisa Anderson

Lisa Anderson

St George’s Hospital, London, UK

Dr Lisa Anderson is a Heart Failure Consultant and Honorary Reader in the Cardiovascular Clinical Academic Group, Molecular and Clinical Sciences Research Institute at St George's Hospital in London, UK.

View full profile

Stephen J Greene

Duke Clinical Research Institute, Duke University School of Medicine, North Carolina, US

Dr Greene is a cardiologist with a clinical and research interest in improving quality of care and outcomes for patients with heart failure.

View full profile
This course is not accredited

Related Courses

An Expert Approach to Cardio-Renal Protection in CKD
  • 2.00 EBAC

Learning objectives

  • Recall clinical evidence and guidelines for the management of CKD patients without diabetes
  • Describe current gaps and barriers in evidence-based management for CKD without diabetes
  • Apply evidence based-management strategies to a case study
  • Use expert-led guidance to develop an optimal management approach to CKD patients without diabetes
See more
Implementing Heart Failure Guidelines with Collaborative Care
  • Not accredited

Learning objectives

  • Appraise new updates in heart failure guideline-directed medical therapy (GDMT)
  • Apply latest guideline recommendations to patient cases
  • Describe barriers preventing early initiation of GDMT
  • Identify the roles of nurses and other healthcare professionals to achieve optimal heart failure therapy
  • Identify the importance of the nurse/cross-functional team
See more
The Advancing Management of Transthyretin Amyloidosis
  • 1.00 EBAC

Learning objectives

  • To differentiate ATTR phenotypes based on presenting signs and symptoms.
  • To select appropriate tests to monitor symptomatic ATTR-cm from imaging, biomarker, functional and QoL assessments.
  • To recall how to identify disease progression across ATTR-cm.
  • To describe the different disease modifying treatments for ATTR including novel agents.
See more
Overcoming the Challenges in Optimising GDMT in HF
  • Not accredited

Learning objectives

  • Appraise the urgency needed in rapid initiation of GDMT to improve HF outcomes.
  • Recognise barriers preventing the use of GDMT in current practice.
  • Identify strategies needed to drive implementation of GDMT in clinical practice.
See more
Hyperkalaemia in Cardiorenal Disease – A Case Based Discussion
  • Not accredited

Learning objectives

  • Explain the relationship between sub-optimal RAASi therapy and poor cardio-renal outcomes
  • Identify patients who would benefit from anti-hyperkalaemia medications
  • Select appropriate anti-hyperkalaemia treatments across a range of patient profiles
  • Adopt anti-hyperkalaemia medications as an approach to prolong optimal RAASi therapy
  • Summarise current guideline recommendations on the use of potassium binding agents
See more
Examining a Complex Heart Failure Case
  • 1.00 EBAC

Learning objectives

  • Identify individuals likely to have HFpEF from initial presentation
  • Refer suspected individuals for specialist assessment
  • Initiate GDMT for HF as soon as patients are stable 
  • Initiate GDMT in HF regardless of EF and phenotype
  • Initiate shared decision-making on complex HF patients with other members of the multidisciplinary team including cardiologists, GPs, nephrologists and diabetologists
See more
Obstructive Hypertrophic Cardiomyopathy: Getting It Right First Time
  • 1.00 EBAC

Learning objectives

  • Recall the general approach to diagnosis and stratification of HCM according to the latest guidelines and expert opinion
  • Apply advanced echocardiographic methodologies to equivocal HCM diagnoses
  • Select appropriate imaging modalities to facilitate accurate risk stratification
  • Stratify patients based on specific risk features and disease severity
  • Choose suitable treatment modalities for patients based on specific disease features and severity
See more
Incorporating GDMT and PRO Endpoints for Personalised HF Management
  • 1.00 EBAC

Learning objectives

  • Review current GDMT in HFrEF and HFpEF
  • Describe the relationship between initiation of GDMT and HF outcomes
  • Prescribe GDMT according to current international recommendations
  • Recall the elements of the Kansas City Cardiomyopathy Questionnaire
  • Describe the clinical studies that support the use of functional and QoL measures in practice
  • Initiate quality of life and functional improvement measures in routine practice
  • Initiate SGLT-2 inhibitors in patients presenting with De novo HF and in patients already on other GDMT
  • Adopt shared decision-making with HF patients
See more
Changing Paradigms in Therapy to Unmet Needs
  • 1.00 EBAC

Learning objectives

  • Recall the utility of EF in heart failure treatment, patient selection and treatment response 
  • Identify alternative measures to EF for the purposes HF severity and therapeutic efficacy 
  • Incorporate quality of life measures for assessing therapeutic efficacy in HF 
  • Recall outcomes from heart failure trials from recent congress and publications and their impact on practice 
See more
SGLT-2 Inhibitors - Another Piece of the Puzzle in Heart Failure
  • 1.00 EBAC

Learning objectives

  • Recall the results of key trials in HFmrEF in different patients' sub-groups
  • Describe how SGLT-2 inhibitors can be used across the range of LVEF
  • Apply emerging diagnostic approaches for HFpEF and HFmrEF
  • Implement best-practice strategies across the range of LVEF
See more